A block-randomized , single-blind , placebo-controlled phase I trial HIV-CORE 002 administered for the first time candidate HIV-1 - vaccines or placebo to 32 healthy HIV-1 / 2-uninfected adults in Oxford , UK and elicited high frequencies of HIV-1-specific T cells capable of inhibiting HIV-1 replication in vitro .